This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aravive Förvaltning

Förvaltning kriterier kontrolleras 0/4

Vi har för närvarande inte tillräcklig information om VD:n.

Viktig information

Verkställande direktör

n/a

Total ersättning

VD-lön i procent	n/a
Anställning som VD	no data
Ägande av VD	n/a
Ledningens genomsnittliga anställningstid	inga uppgifter
Styrelsens genomsnittliga mandatperiod	inga uppgifter

Senaste uppdateringar av ledningen

Recent updates

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

VD OCH KONCERNCHEF

Aravive inte har någon VD, eller så har vi inga uppgifter om dem.

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2024/01/29 08:32
Aktiekurs vid dagens slut	2024/01/29 00:00
Intäkter	2023/09/30
Årlig intjäning	2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Aravive, Inc. bevakas av 16 analytiker. av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
null null	BTIG
John Newman	Canaccord Genuity
Louise Chen	Cantor Fitzgerald & Co.

This company listing is no longer active

Aravive Förvaltning

Förvaltning kriterier kontrolleras 0/4

Viktig information

Senaste uppdateringar av ledningen

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc., Annual General Meeting, Oct 02, 2023

High number of new directors

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Recent updates

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Aravive, Inc., Annual General Meeting, Oct 02, 2023

Consensus revenue estimates decrease by 51%

Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Consensus revenue estimates increase by 95%

Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 35%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian

Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aravive, Inc. announced that it has received $41.559988 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC, and other investors

Consensus forecasts updated

Aravive, Inc. announced that it expects to receive $41.55547 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC

Consensus forecasts updated

Aravive Receives Third Development Milestone from 3D Medicines

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Aravive Q2 GAAP EPS misses, revenue beats

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive appoints Robert Geller as CMO

Price target decreased to US$18.20

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 25%

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

High number of new directors

Consensus forecasts updated

Price target decreased to US$19.75

Aravive, Inc. Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Aravive, Inc. Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

High number of new directors

Aravive, Inc. announced that it has received $10.000001 million in funding from Eshelman Ventures, LLC

Aravive, Inc. announced that it expects to receive $10.000001 million in funding from Eshelman Ventures, LLC

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Consensus revenue estimates increase to US$7.34m

Aravive, Inc.(NasdaqGS:ARAV) dropped from Russell Microcap Growth Index

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Consensus revenue estimates increase to US$4.10m

Aravive, Inc. Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive EPS beats by $0.01, misses on revenue

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Insider exercised options to buy US$318k worth of stock.

Consensus revenue estimates increase to US$3.11m

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Full year 2020 earnings released: US$1.93 loss per share (vs US$1.57 loss in FY 2019)

Aravive, Inc. Announces Updated Data from Its Phase 1B Trial Evaluating Avb-500 in Platinum Resistant Ovarian Cancer

Aravive, Inc. Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

New 90-day high: US$6.85

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth